GSK May Exit Treximet Spat But Remain On Hook

By Melissa Lipman (April 28, 2009, 12:00 AM EDT) -- After pulling GlaxoSmithKline PLC into a patent spat over Pozen Inc.'s migraine treatment Treximet, defendant Par Pharmaceutical Inc. has agreed to drop the British pharmaceutical giant from Pozen's infringement suit in light of GSK agreeing to provide discovery and abide by the court's judgment in the consolidated action....

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!